Ligand Pharma (LGND) Stock Forecast & Price Target

Compare

816 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LGND Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Ligand

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LGND Stock 12 Month Forecast

Average Price Target

$140.00

▲(12.02%Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Ligand Pharma in the last 3 months. The average price target is $140.00 with a high forecast of $157.00 and a low forecast of $108.00. The average price target represents a 12.02% change from the last price of $124.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","158":"$158","101.75":"$101.8","120.5":"$120.5","139.25":"$139.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$157.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$108.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,101.75,120.5,139.25,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.56,115.97846153846154,119.39692307692307,122.81538461538462,126.23384615384616,129.6523076923077,133.07076923076923,136.48923076923077,139.90769230769232,143.32615384615386,146.74461538461537,150.16307692307691,153.58153846153846,{"y":157,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.56,114.67076923076924,116.78153846153846,118.8923076923077,121.00307692307692,123.11384615384615,125.22461538461539,127.33538461538461,129.44615384615383,131.55692307692308,133.6676923076923,135.77846153846156,137.88923076923078,{"y":140,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.56,112.20923076923077,111.85846153846154,111.50769230769231,111.15692307692308,110.80615384615385,110.45538461538462,110.10461538461539,109.75384615384615,109.40307692307692,109.05230769230769,108.70153846153846,108.35076923076923,{"y":108,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.85,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$157.00

Average Price Target$140.00

Lowest Price Target$108.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$119

Hold

-4.78%

Downside

Reiterated

07/02/25

Ligand Pharmaceuticals' overall stock score reflects a mixed financial performance with operational challenges. However, strong technical indicators and positive corporate developments provide a buffer. The earnings call and recent mergers highlight growth potential and strategic direction, contributing to a moderately favorable outlook.

Matt HewittCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

07/02/25

Ligand Pharma (LGND) Gets a Buy from Craig-Hallum

Dex GenotekAI Firm

AI Firm

$103→$108

Hold

-13.59%

Downside

Reiterated

06/07/25

Robert WassermanBenchmark Co.

Benchmark Co.

$135

Buy

8.02%

Upside

Reiterated

05/09/25

Ligand Pharma's Strong Q1 Performance and Strategic Moves Justify Buy Rating with $135 Price Target

Douglas MiehmRBC Capital

RBC Capital

$155

Buy

24.02%

Upside

Reiterated

05/09/25

Trevor AllredOppenheimer

Oppenheimer

$142→$145

Buy

16.02%

Upside

Reiterated

05/09/25

Ligand price target raised to $145 from $142 at OppenheimerLigand price target raised to $145 from $142 at Oppenheimer

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$157

Buy

25.62%

Upside

Reiterated

05/08/25

Positive Outlook for Ligand Pharma: Strong Financial Performance and Strategic Positioning Justify Buy Rating

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$143

Buy

14.42%

Upside

Initiated

04/10/25

Ligand initiated with a Buy at StifelLigand initiated with a Buy at Stifel

Balaji PrasadBarclays

Barclays

$160

Buy

28.02%

Upside

Reiterated

03/10/25

Barclays Keeps Their Buy Rating on Ligand Pharma (LGND)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$119

Hold

-4.78%

Downside

Reiterated

07/02/25

Matt HewittCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

07/02/25

Ligand Pharma (LGND) Gets a Buy from Craig-Hallum

Dex GenotekAI Firm

AI Firm

$103→$108

Hold

-13.59%

Downside

Reiterated

06/07/25

Robert WassermanBenchmark Co.

Benchmark Co.

$135

Buy

8.02%

Upside

Reiterated

05/09/25

Ligand Pharma's Strong Q1 Performance and Strategic Moves Justify Buy Rating with $135 Price Target

Douglas MiehmRBC Capital

RBC Capital

$155

Buy

24.02%

Upside

Reiterated

05/09/25

Trevor AllredOppenheimer

Oppenheimer

$142→$145

Buy

16.02%

Upside

Reiterated

05/09/25

Ligand price target raised to $145 from $142 at OppenheimerLigand price target raised to $145 from $142 at Oppenheimer

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$157

Buy

25.62%

Upside

Reiterated

05/08/25

Positive Outlook for Ligand Pharma: Strong Financial Performance and Strategic Positioning Justify Buy Rating

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$143

Buy

14.42%

Upside

Initiated

04/10/25

Ligand initiated with a Buy at StifelLigand initiated with a Buy at Stifel

Balaji PrasadBarclays

Barclays

$160

Buy

28.02%

Upside

Reiterated

03/10/25

Barclays Keeps Their Buy Rating on Ligand Pharma (LGND)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ligand Pharma

1 Month

xxx

Success Rate

20/34 ratings generated profit

Average Return

+1.52%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +1.52% per trade.

3 Months

xxx

Success Rate

22/34 ratings generated profit

Average Return

+6.96%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +6.96% per trade.

1 Year

Matt HewittCraig-Hallum

Success Rate

25/34 ratings generated profit

Average Return

+14.35%

reiterated a buy rating yesterday

Copying Matt Hewitt's trades and holding each position for 1 Year would result in 73.53% of your transactions generating a profit, with an average return of +14.35% per trade.

2 Years

xxx

Success Rate

27/34 ratings generated profit

Average Return

+26.28%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 79.41% of your transactions generating a profit, with an average return of +26.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LGND Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LGND has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. LGND average Analyst price target in the past 3 months is 140.00.

Each month's total comprises the sum of three months' worth of ratings.

LGND Financial Forecast

LGND Earnings Forecast

Next quarter’s earnings estimate for LGND is $1.42 with a range of $1.27 to $1.73. The previous quarter’s EPS was $1.33. LGND beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.06% of the time in the same period. In the last calendar year LGND has Outperformed its overall industry.

LGND Sales Forecast

Next quarter’s sales forecast for LGND is $43.87M with a range of $38.07M to $48.29M. The previous quarter’s sales results were $45.33M. LGND beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year LGND has Outperformed its overall industry.

LGND Stock Forecast FAQ

What is LGND’s average 12-month price target, according to analysts?

Based on analyst ratings, Ligand Pharma’s 12-month average price target is 140.00.

What is LGND’s upside potential, based on the analysts’ average price target?

Ligand Pharma has 12.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LGND a Buy, Sell or Hold?

Ligand Pharma has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ligand Pharma’s price target?

The average price target for Ligand Pharma is 140.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $157.00 ,the lowest forecast is $108.00. The average price target represents 12.02% Increase from the current price of $124.98.

What do analysts say about Ligand Pharma?

Ligand Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of LGND?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ligand Pharma (LGND) Stock Forecast & Price Target

LGND Analyst Ratings

LGND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ligand Pharma

LGND Analyst Recommendation Trends

LGND Financial Forecast

LGND Earnings Forecast

LGND Sales Forecast

LGND Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts